Paper of the Month - March, 2012

0 rating

Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA.

Volinia S, Galasso M, Sana ME et al.
Until the introduction of mammographic screening, very few ductal breast cancers were diagnosed at the ductal carcinoma in situ stage (DCIS). Now around 15–25% of newly diagnosed breast cancers are DCIS, but defining which of these will progress to invasive breast cancer (IBC) is an unsolved clinical problem resulting in the possible overtreatment of a number of patients. Interestingly, in situ carcinomas and IBCs of the same histological subtype essentially share genetic and epigenetic alterations and expression patterns. In contrast, breast carcinomas of different molecular subtypes, defined by their expression signatures, are quite different in terms of patterns of expression. In the current study, the authors looked at the expression of microRNA (miRNA) that are regulated in the transition from normal breast epithelium to DCIS to invasive ductal carcinoma (IDC).


Breast Cancer Poll 1
What approach do you currently use for the treatment of patients with HER2-overexpressing metastatic breast cancer whose disease has progressed despite trastuzumab?

Powered by NetPolls